Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
Provided By GlobeNewswire
Last update: May 22, 2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that its lead compound, Hydronidone (F351), met the primary endpoint in a pivotal Phase 3 trial evaluating its efficacy and safety for the treatment of liver fibrosis in patients with chronic hepatitis B (“CHB”) in China.
Read more at globenewswire.com9.07
-0.39 (-4.12%)
Find more stocks in the Stock Screener
GYRE Latest News and Analysis
9 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
9 days ago - ChartmillLet's take a look at the stocks that are in motion in today's session.Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
10 days ago - ChartmillDiscover the top movers in Friday's pre-market session.As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
10 days ago - ChartmillThursday's after hours session: top gainers and losersAs the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
